021-51111890
购物车（）
sales@molnova.cn
Bucolome
CAS No. 841-73-6
Bucolome ( Paramidin | Paramidine | Bucolomum | 5-Butyl-1-cyclohexylbarbituric acid | Bucolom )
产品货号. M26078 CAS No. 841-73-6
Bucolome 是一种 CYP2C9 抑制剂，用作抗炎剂或促尿酸排泄剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1017 | 有现货 |
|
| 10MG | ￥1492 | 有现货 |
|
| 25MG | ￥2306 | 有现货 |
|
| 50MG | ￥3171 | 有现货 |
|
| 100MG | ￥4140 | 有现货 |
|
| 200MG | ￥5571 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥884 | 有现货 |
|
生物学信息
-
产品名称Bucolome
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Bucolome 是一种 CYP2C9 抑制剂，用作抗炎剂或促尿酸排泄剂。
-
产品描述Bucolome is a CYP2C9 inhibitor used as an anti-inflammatory agent or uricosuric agent.(In Vitro):In studies with recombinant human cytochrome P-450 2C9 and liver microsomes, Bucolome is a potent mixed-type inhibitor for (S)-warfarin 7-hydroxylation, with Ki of 8.2 and 20.2 microM, respectively.
-
体外实验Bucolome is a potent mixed-type inhibitor for (S)-warfarin 7-hydroxylation, with Ki of 8.2 and 20.2 μM, respectively.
-
体内实验——
-
同义词Paramidin | Paramidine | Bucolomum | 5-Butyl-1-cyclohexylbarbituric acid | Bucolom
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number841-73-6
-
分子量266.341
-
分子式C14H22N2O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCCCCC1C(=O)NC(=O)N(C2CCCCC2)C1=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Williams WG, et, al. 2-Tridecanone: A Naturally Occurring Insecticide from the Wild Tomato Lycopersicon hirsutum f.glabratum. Science. 1980 Feb 22;207(4433):888-9.
产品手册
关联产品
-
α-Factor Mating Pher...
The alpha factor pheromone arrests yeast in the G1 phase of their cell cycle. Alpha Factor Mating Pheromone induces the expression of mating genes, changes in nuclear architecture, and polarzes growth toward the mating partner.
-
Ferulic acid 4-O-sul...
Ferulic acid 4-O-sulfate (Ferulic acid 4-sulfate) 是 Ferulic acid (HY-N0060) 的代谢物。Ferulic acid 4-O-sulfate 可以放松小鼠的动脉，降低血压。
-
2,6-Dimethoxyphenol
2,6-二甲氧基苯酚是一种天然产物，可用于漆酶活性的测定。
